Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 6,448 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Kidney Clear all

Conditions: Renal Cell Carcinoma (Kidney Cancer)
Interventions: 111In-XYIMSR-01; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Graft Rejection, Kidney Disease
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiac Surgery
Interventions: Oxygen - normoxia, Oxygen - hyperoxia; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Pazopanib, Sorafenib, Radium-223; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Nephrogenic Systemic Fibrosis
Interventions: Ablavar; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: New York, New York • Durham, North Carolina

Conditions: Treatment Resistant Nephrotic Syndrome
Interventions: ACTHAR gel; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Focal Glomerulosclerosis
Interventions: Rosiglitazone (Avandia), Adalimumab (Humira); Drug
Lead sponsor: Northwell Health; Other
Eligibility: 2 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 2
States / cities: New Hyde Park, New York • Chapel Hill, North Carolina

Conditions: Aortic Valve Stenosis, Renal Insufficiency, Contrast-induced Nephropathy
Interventions: Remote ischemic preconditioning, Control; Procedure
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Infections, Bacterial
Interventions: Gepotidacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota

Conditions: Mucositis, Graft-versus-host Disease
Interventions: Tac+MTX, TAC + MMF; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: Not listed
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Blood Pressure
Interventions: Radiation Dose 25 Gy, Radiation Dose 50 Gy; Radiation
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years to 85 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Kidney Diseases, Eye Diseases, Cardiac Disease, Surgery, Low Back Pain
Interventions: Multicomponent Physician Performance Peer-Comparison Feedback Intervention; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 5,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Clear Cell Renal Carcinoma
Interventions: MK-3475, Bevacizumab; Drug
Lead sponsor: Arkadiusz Z. Dudek, MD; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 9
States / cities: Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 5 more

Conditions: Kidney Stone
Interventions: iPhone Application, Android Application; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: End Stage Renal Disease (ESRD)
Interventions: ClearGuard HD end cap; Device
Lead sponsor: Pursuit Vascular, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET), Unspecified Childhood Solid Tumor, Protocol Specific, Wilms Tumor and Other Childhood Kidney Tumors
Interventions: pharmacological study, laboratory biomarker analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 16 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 36
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 31 more

Conditions: Chronic Kidney Disease
Interventions: Not listed
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: IGA Nephropathy
Interventions: Fostamatinib 150 mg, Fostamatinib 100 mg, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: Palo Alto, California • Augusta, Georgia • Columbus, Ohio + 1 more

Conditions: Lupus Nephritis
Interventions: Mycophenolate Mofetil; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years to 20 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more

Conditions: Kidney Failure, Chronic, Heart Failure
Interventions: Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Jackson, Mississippi

Conditions: Renal Cell Carcinoma
Interventions: Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection, Adjuvant Pembrolizumab; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prehypertension
Interventions: DASH; Other
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Failure Chronic, Hepatitis C
Interventions: glecaprevir/pibrentasvir treatment; Drug
Lead sponsor: Raymond Chung; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more

Conditions: Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Bronchial Neoplasms, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Digestive System Neoplasms, Endocrine Gland Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Breast Neoplasms, Breast Diseases, Renal Neoplasm, Solid Tumors
Interventions: Entinostat, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants

Risk of Oxygen During Cardiac Surgery Trial

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR

Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)

Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)

Remote Ischemic Preconditioning for Renal Protection in TAVI

Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function

Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX

Renal Denervation in Patients With Uncontrolled Blood Pressure

Smarter Care Virginia, Examining Low-Value Care in Virginia

Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:

Fluid Intake Application to Reduce Kidney Stone Risks

Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap

Evaluating Dactinomycin and Vincristine in Young Patients With Cancer

Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Empagliflozin in ESKD - A Feasibility Study

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

When the Kidney Reacts to Nutritional Changes

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors